Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
346.19M
Enterprise Value
1.63B
Income
87.50M
Sales
1.02B
Book/sh
-10.81
Cash/sh
3.85
Employees
1850
IPO
Mar 22, 2022
P/E
4.12
Forward P/E
3.46
PEG
-
P/S
0.34
P/B
-
P/C
1.59
P/FCF
2.10
EV/EBITDA
5.04
EV/Sales
1.60
Quick Ratio
1.17
Current Ratio
1.68
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
1.48
EPS next Y
1.76
EPS next Q
0.29
EPS this Y
-37.76%
EPS next Y
-3.96%
EPS next 5Y
-12.88%
EPS past 3/5Y
-25.52% -
Sales past 3/5Y
-1.47% -0.10%
EPS Y/Y TTM
4.11%
Sales Y/Y TTM
-7.60%
EPS Q/Q
-53.64%
Sales Q/Q
-8.05%
Insider Own
8.24%
Insider Trans
2.38%
Inst Own
88.83%
Inst Trans
-21.44%
ROA
7.22%
ROE
-
ROIC
11.83%
Gross Margin
59.63%
Oper. Margin
26.38%
Profit Margin
8.59%
SMA20
-5.12%
SMA50
2.05%
SMA200
-0.44%
Trades
Shs Outstand
56.66M
Shs Float
51.99M
52W High
14.81 -58.73%
52W Low
2.77 120.58%
Volatility
4.64% 5.07%
ATR (14)
0.32
RSI (14)
46.15
Beta
0.80
Rel Volume
0.00
Avg Volume
1.04M
Volume
34
Perf Week
-4.98%
Perf Month
-1.61%
Perf Quarter
12.73%
Perf Half Y
110.69%
Perf YTD
-48.57%
Perf Year
-57.30%
Perf 3Y
-63.26%
Perf 5Y
-
Perf 10Y
-
Prev Close
6.25
Price
6.11
Change %
-2.24%
Consensus
Hold
Avg. Price Target
$4.00
Implied Upside
-34.5%
Analysts5incl. previous ratings
Rating Distribution0 Buy · 4 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 06, 2026Downgrade
BBTIG Research
Buy → Neutral
Apr 10, 2025Initiated
MFG logoMMizuho
Neutral$15+145.5%
Dec 02, 2024Upgrade
MS logoMMorgan Stanley
Underweight → Equal-Weight$13 → $20+227.3%
Nov 27, 2024Upgrade
BBTIG Research
Neutral → Buy$26+325.5%
Oct 20, 2023Initiated
WWolfe Research
Peer Perform
Jan 06, 2023Downgrade
MS logoMMorgan Stanley
Equal-Weight → Underweight$28+358.3%
Sep 08, 2022Initiated
BBTIG Research
Neutral
Aug 01, 2022Initiated
MS logoMMorgan Stanley
Equal-Weight$33+440.1%
Jun 21, 2022Initiated
BAC logoBBofA Securities
Underperform$25+309.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morris Milton MayoDirectorSep 04 '26Sale5.886,29336,97153,828Sep 08 05:13 PM
Morris Milton MayoDirectorSep 04 '26Proposed Sale5.866,29336,891Sep 04 03:07 PM
Kurdikar DevdattPresident and CEOAug 12 '26Buy4.7030,000140,937804,919Aug 13 10:50 AM
Elguicze JacobSVP and CFOAug 12 '26Buy4.6720,00093,360309,139Aug 13 10:48 AM
Mann Jeffrey ZPres, Pharm Svc&Prod Mgmt, CLOAug 12 '26Buy4.9920,00099,800262,915Aug 13 10:47 AM
HOMBACH ROBERT J.DirectorAug 12 '26Buy4.9745,000223,848109,587Aug 13 10:45 AM
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
PresidentMr. Devdatt Kurdikar Ph.D.
Senior VP & CFOMr. Jacob P. Elguicze
Senior VPMr. Jeffrey Z. Mann
Senior VP & Chief Human Resources OfficerMs. Jean M. Casner
Senior Vice President of Global Manufacturing & Supply ChainMr. Shaun Curtis